FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-12-23
DOI
10.3389/fonc.2020.612880
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
- (2020) Catherine C. Smith et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity
- (2020) Yik Andy Yeung et al. MOLECULAR THERAPY
- Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
- (2020) Raghuveer Singh Mali et al. HAEMATOLOGICA
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2020) Ali Bazarbachi et al. HAEMATOLOGICA
- Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
- (2020) Tobias Herold et al. LEUKEMIA
- GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo
- (2020) Yuting Wang et al. Translational Oncology
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
- (2020) Sung Choe et al. Blood Advances
- A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
- (2020) Catherine C. Smith et al. Blood Advances
- First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations
- (2020) Naval Daver et al. Frontiers in Oncology
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
- (2019) Haijiao Zhang et al. Nature Communications
- Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia (AML)
- (2019) Richard T. Maziarz et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
- (2019) Jae Yoon Jeon et al. INVESTIGATIONAL NEW DRUGS
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells
- (2019) Nathalie Javidi-Sharifi et al. eLife
- Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia
- (2019) Jun Ma et al. CLINICAL CANCER RESEARCH
- High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations
- (2019) Barbora Brodská et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Martin S. Tallman et al. Journal of the National Comprehensive Cancer Network
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia
- (2019) Changnian Liu et al. BLOOD
- Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
- (2019) Eunice S. Wang et al. BLOOD
- Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease
- (2019) Sabine Kayser et al. BLOOD
- Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib
- (2019) Cheryl A Cohler Peretz et al. BLOOD
- Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
- (2019) Aaron D Goldberg et al. BLOOD
- HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study
- (2019) Naval G. Daver et al. BLOOD
- A Phase II Study of Midostaurin and 5-Azacitidine for Untreated FLT3 Wild Type Elderly and Unfit Acute Myelogenous Leukemia Patients
- (2019) Benjamin K. Tomlinson et al. Clinical Lymphoma Myeloma & Leukemia
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
- (2019) Konstanze Döhner et al. BLOOD
- Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia
- (2018) Brenda Chyla et al. AMERICAN JOURNAL OF HEMATOLOGY
- Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia (AML)
- (2018) Maro Ohanian et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2b study of two dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML
- (2018) Jorge E. Cortes et al. BLOOD
- Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
- (2018) Ying Wang et al. Journal of Hematology & Oncology
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
- (2018) Hardikkumar Jetani et al. LEUKEMIA
- Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
- (2018) Lynn Quek et al. NATURE MEDICINE
- Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
- (2018) Richard F. Schlenk et al. BLOOD
- Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
- (2017) S.K. Metzelder et al. EUROPEAN JOURNAL OF CANCER
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
- (2017) M Wattad et al. LEUKEMIA
- The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
- (2017) Hamid Bolouri et al. NATURE MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD–Positive Acute Myelogenous Leukemia
- (2016) Betül Oran et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
- (2016) I. Z. Uras et al. BLOOD
- Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
- (2016) Lauren Y. Lee et al. BLOOD
- How I treat FLT3-mutated AML
- (2016) Keith W. Pratz et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
- (2016) Steven Knapper et al. BLOOD
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission
- (2016) Andrew M. Brunner et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2016) Karoline Kollmann et al. CANCER CELL
- Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
- (2016) Jeng-Wei Lu et al. CANCER LETTERS
- FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
- (2016) Elie Traer et al. CANCER RESEARCH
- Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms
- (2016) Chun Hang Au et al. Diagnostic Pathology
- MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia
- (2016) B Xu et al. LEUKEMIA
- Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia
- (2016) Alison R. Walker et al. LEUKEMIA & LYMPHOMA
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
- (2016) O Lindblad et al. ONCOGENE
- Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
- (2016) Wenlan Chen et al. PLoS One
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
- (2015) Paolo Strati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation
- (2015) A. Tschan-Plessl et al. ANNALS OF HEMATOLOGY
- Secondary mutations as mediators of resistance to targeted therapy in leukemia
- (2015) N. Daver et al. BLOOD
- Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells
- (2015) C. Larrue et al. BLOOD
- A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations
- (2015) Walter Fiedler et al. BRITISH JOURNAL OF HAEMATOLOGY
- High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation
- (2015) Tiago De Freitas et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
- (2015) H Wu et al. LEUKEMIA
- Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
- (2015) I-K Park et al. LEUKEMIA
- The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
- (2015) E Chang et al. LEUKEMIA
- Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy
- (2015) Fangfang Wang et al. LEUKEMIA RESEARCH
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397
- (2015) C. C. Smith et al. Cancer Discovery
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
- (2014) Yi-Bin Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
- (2014) H. K. Lee et al. BLOOD
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia
- (2014) H. S. Ma et al. CANCER RESEARCH
- Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol
- (2014) N. Bolli et al. HAEMATOLOGICA
- Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
- (2014) K. Keegan et al. MOLECULAR CANCER THERAPEUTICS
- Crenolanib is a selective type I pan-FLT3 inhibitor
- (2014) C. C. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
- (2013) C. C. Smith et al. BLOOD
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
- (2013) Neil P. Shah et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
- (2013) Xiaochuan Yang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
- (2013) Catherine Dutreix et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
- (2013) S. D. Baker et al. CLINICAL CANCER RESEARCH
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
- (2013) Casey B. Williams et al. PHARMACOTHERAPY
- Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
- (2013) Karthika Natarajan et al. PLoS One
- Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
- (2012) Susanne Schnittger et al. GENES CHROMOSOMES & CANCER
- The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220
- (2012) D. Pauwels et al. HAEMATOLOGICA
- Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next-Generation Sequencing Data
- (2012) David H. Spencer et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia
- (2012) A Y H Leung et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
- (2011) Amy E. DeZern et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
- (2011) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
- (2010) Michael Crump et al. LEUKEMIA & LYMPHOMA
- Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
- (2009) S. Kayser et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Clinical implications of c-Kit mutations in acute myelogenous leukemia
- (2009) Muriel Malaise et al. Current Hematologic Malignancy Reports
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started